Unternehmen Antibe Therapeutics Inc Toronto S.E.
Aktien
ATE
CA0370251039
ATE
Biotechnologie
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01.12.15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 01.01.16 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 06.05.20 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 01.11.12 |
Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 50 | 24.11.20 | |
Amal Khouri
BRD | Director/Board Member | - | 19.03.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 53 009 362 | 48 481 043 ( 91,46 %) | 0 | 91,46 % |
Unternehmenskontakt
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+9.42% | 114 Mrd. | |
+11.84% | 104 Mrd. | |
-14.15% | 22.41 Mrd. | |
-1.05% | 22.28 Mrd. | |
-5.29% | 19.07 Mrd. | |
-38.29% | 18 Mrd. | |
-4.16% | 17.89 Mrd. | |
+7.99% | 14.28 Mrd. | |
+36.24% | 12.55 Mrd. |